Western European Endoscopic Devices Market To Benefit From Increase In Minimally Invasive Surgeries, Says Frost & Sullivan
LONDON, April 10, 2013 /PRNewswire/ -- The rise in the number of minimally invasive surgeries (MIS) is promoting the use of endoscopy devices. These devices provide the necessary visualisation during MIS procedures.
New analysis from Frost & Sullivan ( http://www.medtech.frost.com), Western European Endoscopy Devices Market, finds that the market earned revenues of $2.96 billion in 2012 and estimates this to reach $4.44 billion in 2019. The research covers the potential for rigid and flexible endoscopes and endoscopy equipment and accessories across applications in arthroscopy, ENT, gastrointestinal, gynaecology, laparoscopy, neurology, pulmonary and urology.
"In the existing managed care environment, MIS procedures – which offer both clinical and cost benefits – are increasing at a faster pace than conventional surgical procedures," notes Frost & Sullivan Healthcare Research Analyst Brahadeesh Chandrasekaran. "This is expected to be a key driving factor for endoscopy devices."
Endoscopy's advantage over traditional surgery is attributed to its ability to provide a visual, while being minimally invasive. This is motivating the use of these devices in various surgical techniques. For instance, endoscopy techniques such as arthroscopy, a major surgical endoscopic technique that focused primarily on the knee, is now expanding to other areas such as the shoulder, the wrist and small peripheral joints.Endoscopy has become a common procedure in various fields such as urology, gynaecology and gastroenterology. In the future, endoscopy may be the standard procedure for the diagnosis and treatment of most internal organ disorders, as well as for the treatment of liver, colorectal and other types of cancer. "The sale of technologically advanced products, such as video-endoscopes and capsule endoscopes, indicate that there is a huge demand for advanced, innovative products," adds Chandrasekaran. "Although these devices are initially challenged by the lack of reimbursement, penetration levels are set to rise subsequent to strong clinical evidence being provided."
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts